Last reviewed · How we verify
NCT06849128
NeuroReAlign Therapy for Cognitive Rehabilitation in Patients with Stroke
NA trial testing NeuroReAlign Therapy in Stroke in 30 participants. Not yet recruiting.
15 April 2025
Quick facts
| Lead sponsor | Middle East University |
|---|---|
| Phase | NA |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 30 |
| Start date | 15 March 2025 |
| Primary completion | 15 April 2025 |
| Estimated completion | 30 April 2025 |
Drugs / interventions tested
- NeuroReAlign Therapy
- Conventional cognitive training
Conditions studied
- Stroke — all drugs for Stroke →
Sponsor
Middle East University
Who can join
Adults 18 to 70, any sex, with Stroke. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this randomized controlled trial is to investigate the effects of NeuroReAlign Therapy on cognition in stroke survivors in the chronic stage (\>6 months). The study will include male and female participants aged 18-70 years. The main questions it aims to answer are: Does NeuroReAlign Therapy improve cognition in stroke survivors compared to conventional physiotherapy? Researchers will compare NeuroReAlign Therapy to conventional cognitive therapy to determine its effects on cognition. Participants will: Undergo NeuroReAlign Therapy or conventional cognitive therapy for 4 weeks. Have their cognition evaluated using the Montreal Cognitive Assessment (MoCA), Mini-Mental State Examination (MMSE), Trail Making Test (TMT), Stroop Test, Digit Span Test, and Verbal Fluency Test (VFT). Complete outcome assessments at baseline and after the intervention (week 4).
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06849128
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of NeuroReAlign Therapy
Trials testing the same drug.
- NCT06849102 — NeuroReAlign Therapy for Balance and Gait Rehabilitation in Stroke Survivors · NA · not yet recruiting
Other recruiting trials for Stroke
Currently open trials in the same condition.
- NCT06615973 — Screening for Social Determinants of Health (SDOH) and Cognitive Function in Individuals With History of Stroke · recruiting
- NCT07494890 — Measurement Properties of Mechanical Cost of Walking for Individuals With Walking Impairment · NA · recruiting
- NCT07356011 — Exoskeleton for Balance · NA · recruiting
- NCT07523503 — Unilateral Versus Bilateral Task-specific Training on Motor Impairment, Upper Extremity Function, and Hand Dexterity in · NA · recruiting
- NCT06704074 — Virtual Reality Task Oriented Training on Upper Limb Function in Stroke Patients · NA · recruiting
Other Middle East University trials
Trials by the same sponsor.
- NCT07497451 — Enhancing Pain Management Among Patients Diagnosed With Stage III and Stage IV of Breast Cancer: The Power of Immersive · NA · not yet recruiting
- NCT07466186 — Resistance Training on Depression and Quality of Life in Type 1 Diabetic Women · NA · not yet recruiting
- NCT07324239 — TECAR Therapy on Pain and Quality of Life in Men With Chronic Prostatitis/Chronic Pelvic Pain Syndrome · NA · not yet recruiting
- NCT07278596 — High Intensity Focused Electromagnetic Therapy on Pain and Quality of Life in Patients With Lumbar Disc Prolapse · NA · not yet recruiting
- NCT06849102 — NeuroReAlign Therapy for Balance and Gait Rehabilitation in Stroke Survivors · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06849128 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Middle East University
- Last refreshed: 18 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06849128.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing